Kinaset Therapeutics to Present KN-002 Phase 1 Clinical Study Outcomes at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

12.7.23 Kinaset Therapeutics to Present KN-002 Phase 1 Clinical Study Outcomes at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting BOSTON, MA, December 7, 2023 — Kinaset Therapeutics , a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced an upcoming oral presentation at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held on February 23-26, 2024. Frazer Morgan, Co-founder and Chief Development Officer, will deliver an oral presentation on outcomes from the Phase 1 evaluation of Kinaset’s lead candidate, KN-002, an orally inhaled novel, pan-JAK inhibitor being advanced for the treatment of moderate to severe asthma. Presentation Details: Poster Title: Safety and Pharmacokinetics of Single Ascending Doses of KN-002 in Healthy Volunteers and Multiple Ascending Doses of KN-002 in Subjects with Mild Asthma Session Title: Old Therapeutics and New Targets in Asthma Session Date and Time: Saturday, February 24 at 2:00 p.m. ET Location: Walter E. Washington Convention Center, Washington D.C. More information on the 2024 AAAAI Annual Meeting can be found here . About Kinaset Therapeutics, Inc. Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. The Company’s lead clinical candidate KN-002 is a novel, pan-JAK inhibitor formulated as a dry powder for delivery via the non-invasive oral inhaled route of administration. KN-002 is currently being evaluated in a Phase 1b clinical study involving patients with mild to severe asthma and those with COPD (NCT05006521). With founding investors 5AM Ventures, Atlas Venture and Gimv, the Company is pursuing a patient-focused approach to build a leading respiratory therapeutics company. See more information at the Company’s website . Company Contact Roger Heerman – Chief Business Officer [email protected] +1 508-858-5810 Media Contact MacDougall Shannon Youngberg [email protected] +1 781-235-3060 RETURN TO NEWS

The release as fetched from its publisher. kinasettherapeutics.com ↗